HER2-positive Breast Cancer
Conditions
Brief summary
This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify constitutional genetic factors associated with histological response, resistance or sensibility to treatment in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. 9000 patients will be enrolled in this study. Blood samples will be collected after informed consent and inclusion in the study. Patients will be treated and followed according to the standards of their treating center. They will be followed every six months for five years.
Detailed description
The purpose of the SIGHER trial is to create a cohort of 9000 patients with HER2-positive breast cancer including detailed epidemiologic and treatment data. The distribution of constitutional genetic variants will be evaluated within groups of patients treated with different regimes of targeted therapies, identifying variants associated with histological response, as well as sensitivity or resistance to these therapies. Blood samples will be collected in two 6ml ethylenediaminetetraacetic acid (EDTA) tubes after informed consent and inclusion in the study. As the samples are received at the biological resource center, total blood will be aliquoted into a 500 µl tube and frozen at -80° C. DNA will be extracted using standard protocols. DNA will be stored in anticipation of genetic analyses. An aliquot of the DNA sample will be genotyped for a panel of high-density genetic markers covering the whole genome for genome-wide association studies.
Interventions
Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study
Sponsors
Institut de cancérologie Strasbourg Europe
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For inclusion in the study, patients must be affiliated to the national or local social security, and must meet all the following criteria: Inclusion Criteria: * Age ≥ 18 years * Histological diagnosis of breast adenocarcinoma. Non-metastatic and operable. * Current or prior treatment with one therapy targeting HER2 in adjuvant or neoadjuvant phase for the current breast cancer * Given written informed consent
Exclusion criteria
* Patients not able to comply to the protocol assessments for geographic, social or psychological reasons * Patients placed under judicial protection, guardianship, or supervision * History of cancer in the 5 years preceding anti-HER2 therapy initiation * Concomitant cancer (except for an other non metastatic cancer treated only with surgery) Note : Patients are eligible at any time of the follow-up if the adjuvant or neoadjuvant chemotherapy started after 01/01/2019. Patients treated with trastuzumab, pertuzumab, neratinib or T-DM1 in a clinical trial are eligible in the SIGHER study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic Complete Response (pCR) | at the end of enrollment (3 years) | Constitutional genetic variants using a genome-wide approach will be tested for association with pCR as a function of neoadjuvant treatment targeting HER2. |
| Disease Free Survival (DFS) | At the end of the study (8 years) | Constitutional genetic variants using a genome-wide approach will be tested for association with DFS as a function of treatment |
| Overall Survival (OS) | At the end of the study (8 years) | Constitutional genetic variants using a genome-wide approach will be tested for association with OS as a function of treatment |
Countries
France
Contacts
Primary ContactValérie SARTORI
Backup ContactManon VOEGELIN, PhD
Outcome results
None listed